Keywords: serono, exceeds, 2nd, qtr, forecasts, switzerland-based, biotechnology
Serono exceeds 2nd qtr forecasts
Article | 25 July 2005
Switzerland-based biotechnology group Serono posted a 32.5% rise to $175.1 million in second-quarter 2005 net income, or $12.02 per bearer share and $0.30 per American ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- Elan makes "transformational" acquisitions and a divestment
